Validation of pencil beam scanning proton therapy with multi-leaf collimator calculated by a commercial Monte Carlo dose engine

Yuki Tominaga1,2 | Yusuke Sakurai1 | Junya Miyata2,3 | Shuichi Harada4 | Takashi Akagi4 | Masataka Oita2

1Department of Radiotherapy, Medical Co. Hakuhokai, Osaka Proton Therapy Clinic, Osaka, Japan
2Division of Radiological Technology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama, Japan
3Department of Radiological technology, Kurashiki Central Hospital, Okayama, Japan
4Hyogo Ion Beam Medical Support, Hyogo, Japan

Correspondence
Masataka Oita, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama, Okayama 700–8558, Japan. Email: oita-m@cc.okayama-u.ac.jp

Abstract
This study aimed to evaluate the clinical beam commissioning results and lateral penumbra characteristics of our new pencil beam scanning (PBS) proton therapy using a multi-leaf collimator (MLC) calculated by use of a commercial Monte Carlo dose engine. Eighteen collimated uniform dose plans for cubic targets were optimized by the RayStation 9A treatment planning system (TPS), varying scan area, modulation widths, measurement depths, and collimator angles. To test the patient-specific measurements, we also created and verified five clinically realistic PBS plans with the MLC, such as the liver, prostate, base-of-skull, C-shape, and head-and-neck. The verification measurements consist of the depth dose (DD), lateral profile (LP), and absolute dose (AD). We compared the LPs and ADs between the calculation and measurements. For the cubic plans, the gamma index pass rates (γ-passing) were on average 96.5% ± 4.0% at 3%/3 mm for the DD and 95.2% ± 7.6% at 2%/2 mm for the LP. In several LP measurements less than 75 mm depths, the γ-passing deteriorated (increased the measured doses) by less than 90% with the scattering such as the MLC edge and range shifter. The deteriorated γ-passing was satisfied by more than 90% at 2%/2 mm using uncollimated beams instead of collimated beams except for three planes. The AD differences and the lateral penumbra width (80%–20% distance) were within ±1.9% and ±1.1 mm, respectively. For the clinical plan measurements, the γ-passing of LP at 2%/2 mm and the AD differences were 97.7% ± 4.2% on average and within ±1.8%, respectively. The measurements were in good agreement with the calculations of both the cubic and clinical plans inserted in the MLC except for LPs less than 75 mm regions of some cubic and clinical plans. The calculation errors in collimated beams can be mitigated by substituting uncollimated beams.

KEYWORDS
commissioning, lateral penumbra, multi-leaf collimator, pencil beam scanning, proton therapy
INTRODUCTION

Proton beam therapy has excellent depth dose (DD) physical properties, which enable comparable target dose conformity and lower dose around normal tissues than conventional radiotherapy. Currently, pencil beam scanning proton (PBS) therapy is the most advanced proton therapy, which uses an inverse-planned mono-energetic pencil beam (PB) that scans the target across the lateral plane. The scanned beams also change from high to low energies, creating a dose distribution in the depth direction. PBS enables better dose conformity in the target and reduces the surrounding organs at risk (OARs) compared to both passive scattering and uniform scanning methods.

However, current PBS accelerators can irradiate only up to approximately 70 MeV (approximately 40 mm depth in water). To irradiate superficial regions, we must insert an energy absorber called a range shifter (RS), which expands the lateral fall-off (penumbra) by beam scattering and deteriorates the lateral dose distribution. Although PBS can also avoid critical organs with a distal fall-off, some dose errors are considered, such as range uncertainties and increasing relative biological effectiveness (RBE). To overcome these issues, PBS plans are often preferred for lateral beam angle selection with respect to the location of critical organs. Thus, the PBS beam requires the lateral penumbra to be as steep as possible. Several authors have reported new techniques for improving the penumbra, such as advanced optimizing spot placements, smaller initial beam size machines, and patient-specific aperture systems.

Furthermore, the calculated dose by increasing the distance between the patient and RS (called air gap) deteriorates the penumbra and causes dose discrepancy due to the nuclear halo. To mitigate these effects, the PBS beam should be irradiated with RS as close as possible to the patient’s surface.

Our PBS proton therapy system, which has a multi-leaf collimator (MLC) downstream of a movable nozzle, could be irradiated to patients as close as possible. This machine is the same as the one used in the studies by Fukumitsu and Sugiyama et al. By using the MLC, no additional collimation hardware is required for each beam, thus improving the treatment throughput and reducing the risk of dropping patients. Our commercial treatment planning system (TPS) could also perform Monte Carlo (MC) dose calculations, thus reducing the above mentioned problem of dose discrepancy with an increasing air gap. Although several reports have published planning simulations and commissioning results about using an MLC, no report was found on the TPS validations of this PBS system with the MLC. Here, this study aimed to validate the clinical beam commissioning using the MLC for cubic target volumes of various sizes and clinically realistic plans.

METHODS

2.1 Proton beam therapy system

The Medical Corporation, Osaka Proton Therapy Clinic, has a MELTHEA V (Hitachi, Ltd., Tokyo, Japan) proton beam system. This system has a synchrotron and gantry room with a selected beam nozzle. The users could select both lattice scanning and PBS for raster scanning for each patient. The nozzle with the MLC on the tip could approach the isocenter by a minimum of 250 mm, thus the PBS beam could irradiate with RS and MLC as close as possible to the patient’s surface. Depending on the policy of treatment planning, the PBS system can irradiate both collimated and uncollimated beams in the planning phase. The MLC is used externally from the target by an arbitrary margin. The MLC is positioned stationary outside when all energy layer spots are irradiated. Although the spots and MLC may overlap depending on the distance between the collimator and the target volume, the resulting dose distribution of collimated (cut) spot are also optimized by the TPS. Since the leaf positions can be manually changed, it is possible to hide the specific OAR region from the direction of the beam using several leaves to spare OARs such as the passive scattering method. This PBS system has 70.7–235.0 MeV energies and is available for using seven polyethylene RSs 60–66 mm water-equivalent thickness (WET) downstream of the nozzle to irradiate less than 40 mm. The MLC consists of 54 pairs of leaves and is made of iron with a thickness of 140 mm and a leaf width of 3.75 mm. Individual leaves can extend up to 75 mm in the lateral direction, resulting in a maximum collimator open size of 150 × 200 mm². The distance between the isocenter and MLC varied from 250 to 560 mm, and the maximum field area at

![FIGURE 1](image-url)
the isocenter ranged from 162 × 216 to 184 × 246 mm². More information about this machine can be found in the paper by Fukumitsu et al.14

### 2.2 TPS validation

The RayStation 9A TPS (RaySearch, Stockholm, Sweden) has a commercial MC dose calculation engine.21 The MC must be used for all collimated beams to consider scattering from both the MLC and RS. According to the TPS reference manual, the modeling for the nuclear halo was calculated based on two papers by Soukup et al. and Pedroni et al. in 2005,22,23 These works reported that the width and relative weight of the nuclear scattering Gaussian is calculated as a function of the initial beam energy and the radiological depth. To consider the dose contribution of nuclear interaction, a second ‘nuclear’ pencil beam is used in addition to the PB whose transverse spread is described by the multiple scattering.

Eighteen verification plans for cubic targets were created with field sizes of 40 mm × 40 mm² and 95 mm × 95 mm², various beam ranges, and spread-out Bragg peak (SOBP) widths of 90 mm. All plans consisted of a single field optimized (SFO) beam with a gantry angle of 0°, and the isocenter was determined at the center of the SOBP. The dose calculation grid was 2.0 × 2.0 × 2.0 mm³ for all plans. An RS of 60 mm was used for 9 of the 18 plans, and the three types of 45° snout rotated beams were included for both the RS and without RS plans. The air gaps were set to 150 mm, except for the three shallowest plans without RS (air gap of 164 mm). To cover each target adequately, the MLC leaf margins were determined at 1.4–7.2 mm with respect to each target. The prescribed doses covered 1.0 GyRBE with 98% of each target volume. Table 1 shows the beam parameters for 18 cubic plans. Figure 2 shows a screenshot in the TPS for the representative cubic plan (called Cubic 1 in Table 1).

### 2.3 Verification plans

To evaluate patient-specific TPS validation, we selected three representative clinical cases and the C-shape and head and neck (HN) phantoms of the American Association of Physicists in Medicine (AAPM) Task Group Report 119 (TG-119).24 Lower part of Table 1 shows the beam parameters of five clinical realistic plans. The three clinical cases consisted of liver recurrence of intrahepatic cholangiocarcinoma (liver), prostate cancer (prostate), and skull base chordoma (chordoma). The selected patient information was approved by the institutional review board at Osaka Proton Therapy Clinic (No. 20201016-2). All helical CT scans were acquired in the supine position using an Aquilion LB TSX 201A (Canon, Tokyo, Japan). Since constant respiratory movements were observed in the liver, gated CT scans were acquired using AZ-733 V (Anzai, Tokyo, Japan). The gross tumor volumes (GTVs) and several surrounding OARs were delineated by an experienced oncologist at each site. The clinical target volumes (CTVs) were created by expanding from the GTVs by 5 mm for the liver and chordoma cases excluding the anatomical barriers. The planning target volumes (PTVs) were geometrically expanded from the CTVs by 5 mm for the prostate and 3 mm for the chordoma. For the liver case, the internal target volume (ITV) was expanded by 1–2 mm from the CTV to consider respiratory motion, and the PTV was expanded from the ITV by 5 mm.

The dose prescriptions covered 66 GyRBE in 10 fractions for the liver, 63 GyRBE in 21 fractions for the prostate, and 70 GyRBE in 35 fractions for chordoma, with 50% of each CTV. The beam angles were selected to maintain target coverage and minimize OAR doses; the number of fields was determined with three for the liver and chordoma and two opposite fields for the prostate. Due to the automatic setting for TPS optimization, the RSs of 60–61 mm for the liver and 2 mm for the chordoma were used, and no RS was used for the prostate case. Worst-case optimization was used with setup uncertainty for six directions of ± 5 mm for both the liver and prostate, and ± 3 mm for the chordoma.25 An additional ±3.5% range uncertainties were added to all cases.26 Spot optimization techniques were SFO for the liver and prostate and multi-field optimization (MFO) for chordoma. The spot spacing of all the energy layers was one spot sigma multiplied by 0.8 in water for all plans. To ensure the robustness of the CTV, the MLC was collimated with a margin of 13.0 mm for the liver, 9.0 mm for the prostate, and 8.0 mm for the Chordoma with respect to each CTV. All plans were optimized on a 2 mm calculation grid. Although the TPS could optimize both the PB and the MC algorithms, each optimization algorithm was determined to be the same as our clinic conditions.27 The liver and chordoma plans were optimized using the MC algorithm with a sampling history of 5000 ions/spot, while the prostate plan was optimized using the PB algorithm. Normally, the PBS plans were optimized by the MC algorithm; thus, we use the PB algorithm for prostate plans in plan optimization of clinical use to save planning time. The final dose calculation used the MC algorithm with a 0.5% statistical uncertainty for all plans.

The C-shape and HN plans were created according to the dose constraints presented in the TG-119 with three fields in both plans. The optimization algorithm, statistical uncertainty, and calculation grid were used at 5000 ions/spot, 0.5%, and 2.0 mm, respectively. The C-shape plan was satisfied with the hard constraints (10% volume to receive less than 10 GyRBE) of the core OAR and 95% of the PTV to receive 50 GyRBE (ref 24 in Table 624). The HN plan could satisfy all dose constraints.
### Table 1

| Beam name | Gantry (°) | Snout (°) | Isocenter (mm) | Range (mm) | RS (mm) | Number of layers | Air gap (mm) | MLC (mm) | Optimize pattern* | Scan pattern | Middle (ranges) gamma passing of lateral profiles at 2%/2 mm (%) |
|-----------|------------|-----------|----------------|-----------|---------|-----------------|-------------|----------|------------------|-------------|--------------------------------------------------------------|
| Cubic 1   | 0          | 0         | 288            | 341.9     | None    | 18              | 150         | 5.1      | PB-MC            | SFO         | 99.4 (73.7–99.4)                                            |
| Cubic 2   | 0          | 0         | 288            | 341.9     | None    | 25              | 150         | 3.1      | PB-MC            | SFO         | 99.2 (63.0–99.2)                                            |
| Cubic 3   | 0          | 0         | 185            | 241.3     | None    | 25              | 150         | 6.1      | PB-MC            | SFO         | 100 (92.0–100.0)                                            |
| Cubic 4   | 0          | 0         | 185            | 241.3     | None    | 52              | 164         | 1.4      | PB-MC            | SFO         | 96.7 (81.8–99.2)                                            |
| Cubic 5   | 0          | 45        | 288            | 341.9     | None    | 18              | 150         | 5.0      | PB-MC            | SFO         | 100 (71.9–100.0)                                            |
| Cubic 6   | 0          | 45        | 185            | 241.3     | None    | 25              | 150         | 5.3      | PB-MC            | SFO         | 100 (97.4–100.0)                                            |
| Cubic 7   | 0          | 45        | 86             | 141.5     | None    | 52              | 164         | 5.0      | PB-MC            | SFO         | 94.2 (83.5–99.3)                                            |
| Cubic 8   | 0          | 0         | 227            | 284.4     | 60.0    | 18              | 150         | 6.4      | PB-MC            | SFO         | 99.4 (89.3–99.4)                                            |
| Cubic 9   | 0          | 45        | 135            | 189       | 60.0    | 22              | 150         | 4.5      | PB-MC            | SFO         | 98.8 (96.6–99.4)                                            |
| Cubic 10  | 0          | 45        | 135            | 189       | 60.0    | 22              | 150         | 6.8      | PB-MC            | SFO         | 100 (100.0–100.0)                                           |
| Cubic 11  | 0          | 0         | 227            | 284.4     | 60.0    | 18              | 150         | 3.3      | PB-MC            | SFO         | 95.6 (93.8–100.0)                                           |
| Cubic 12  | 0          | 45        | 135            | 189       | 60.0    | 36              | 150         | 5.9      | PB-MC            | SFO         | 97.8 (91.9–100.0)                                           |
| Cubic 13  | 0          | 45        | 227            | 284.4     | 60.0    | 18              | 150         | 5.0      | PB-MC            | SFO         | 99.4 (90.1–99.4)                                            |
| Cubic 14  | 0          | 45        | 98             | 98        | 60.0    | 36              | 150         | 6.9      | PB-MC            | SFO         | 93.3 (72.0–100.0)                                           |
| Cubic 15  | 0          | 45        | 98             | 60.0      | 60.0    | 36              | 150         | 5.9      | PB-MC            | SFO         | 98.8 (96.6–99.4)                                            |
| Cubic 16  | 0          | 45        | 98             | 60.0      | 60.0    | 36              | 150         | 6.9      | PB-MC            | SFO         | 100 (100.0–100.0)                                           |
| Cubic 17  | 0          | 45        | 98             | 60.0      | 60.0    | 36              | 150         | 5.0      | PB-MC            | SFO         | 100 (100.0–100.0)                                           |
| Cubic 18  | 0          | 45        | 98             | 60.0      | 60.0    | 36              | 150         | 5.0      | PB-MC            | SFO         | 100 (100.0–100.0)                                           |
| Liver 1   | 30         | 0         | 57             | 85.0      | 61.0    | 24              | 109.2       | 13.0     | MC-MC            | SFO         | 100 (100.0–100.0)                                           |
| Liver 2   | 315        | 0         | 36             | 65.0      | 60.0    | 23              | 116.4       | 13.0     | MC-MC            | SFO         | 100 (100.0–100.0)                                           |
| Liver 3   | 270        | 0         | 36             | 57        | 60.0    | 25              | 99.2        | 13.0     | MC-MC            | SFO         | 100 (100.0–100.0)                                           |
| Prostate 1| 90         | 0         | 196            | 236.3     | None    | 17              | 160.7       | 9.0      | PB-MC            | SFO         | 100 (100.0–100.0)                                           |
| Prostate 2| 270        | 0         | 199            | 241.3     | None    | 17              | 157.5       | 9.0      | PB-MC            | SFO         | 100 (97.4–100.0)                                            |
| Chordoma 1| 280        | 0         | 200            | 139.6     | 2.0     | 38              | 148.0       | 8.0      | MC-MC            | MFO         | 99 (90.2–99.9)                                              |
| Chordoma 2| 280        | 0         | 80             | 138.2     | None    | 43              | 146.7       | 8.0      | MC-MC            | MFO         | 92.8 (91.8–100.0)                                           |
| Chordoma 3| 280        | 0         | 80             | 138.2     | None    | 43              | 146.7       | 8.0      | MC-MC            | MFO         | 99 (98.0–100.0)                                              |
| C-shape 1 | 0          | 0         | 51             | 85.0      | None    | 34              | 199.2       | 5.0      | MC-MC            | MFO         | 96.8 (96.8–100.0)                                           |
| C-shape 2 | 0          | 0         | 127            | 192.3     | None    | 22              | 99.7        | 5.0      | MC-MC            | MFO         | 100 (100.0–100.0)                                           |
| C-shape 3 | 0          | 0         | 127            | 192.3     | None    | 22              | 100.1       | 5.0      | MC-MC            | MFO         | 100 (90.9–100.0)                                            |
| HN 1      | 0          | 0         | 75             | 129.9     | 60.0    | 34              | 57.4        | 5.0      | MC-MC            | MFO         | 86.2 (86.2–98.6)                                            |
| HN 2      | 150        | 0         | 87             | 162.4     | 60.0    | 36              | 93.1        | 5.0      | MC-MC            | MFO         | 98.7 (95.5–100.0)                                           |
| HN 3      | 210        | 0         | 87             | 162.4     | 60.0    | 37              | 94.2        | 5.0      | MC-MC            | MFO         | 98.7 (81.7–100.0)                                           |

*Abbreviations: PB-MC, Pencil beam algorithm optimization followed by Monte Carlo (MC) dose calculation; MC-MC, MC optimization followed by MC dose calculation.

...of the targets and OARs in the Table 6. The 14 collimated beams of the five verification plans were copied to the same water phantom used to calculate the cubic plan. The WET from the patient surface to the isocenter was determined for each isocenter. Figure 2 shows the screenshots in the TPS for each first beam of the five clinical verification plans. The cross line in the figure indicates the isocenters of each plan.

---

### 2.4 Evaluation tools

Beam measurements were performed for the DDs, lateral penumbra widths at the isocenter, lateral profiles (LPs), and absolute doses (ADs) at the isocenter with a gantry angle of 0°. Both DDs and lateral penumbra used the 3-dimensional (3D) water phantom (MP3-M; PTW Freiburg, Germany), six PinPoint ionization chambers...
(Type 31015; PTW), a multi-channel electrometer (MULTIDOS; PTW), and a measurement control software (HRD; HIBMS, Hyogo, Japan). As shown in Figure 3, the measurement attachments of DDs and lateral penumbra are arranged in helical and lateral directions, and each chamber is positioned at 10 mm intervals. The six chambers were arranged so that the chamber hits the dedicated pillar placed in the central axis for DD attachment. Then, a mono-energetic beam (141.2 MeV) was used to check the beam range agreement after setting both DD and lateral penumbra attachments. The cross-calibration between the PinPoint chamber used for port 1 of the MULTIDOS and a calibrated Semiflex ionization chamber (Type 31013; PTW) was measured in the mono-energetic (141.2 MeV) uniform fields of 102 × 102 mm² at a depth of 25 mm. Then, the correction coefficients between the charge of the port 1 chamber and the other chambers were also measured under the same mono-energetic fields and was registered in the MULTIDOS console as the calibration value. Twelve DDs were measured, except for collimator-rotated beams, which were analyzed using the gamma index at the criteria of 3%/3 mm and a dose threshold above 10% of the maximum dose. Then, the lateral penumbra widths (defined as the distance between 80% and 20% with respect to isodose points) at the central axis were measured for all plans in both the x (left-right) and y (superior-inferior) directions at the isocenter. The penumbra widths were compared between the measured values and TPS calculations.

The ADs were measured at the center of the SOBP for all 18 plans, which was the same as the isocenter. Absolute dose measurements were performed using the solid water phantom (Tough Water; Kyoto Kagaku, Kyoto, Japan) and a PinPoint 3D ion chamber (Type 31022; PTW). The Tough Water has a hole in the isocenter for
inserting the 3D PinPoint chamber and is installed so that blocks corresponding to the measurement depth are stacked. The measured physical doses were scaled up by a factor of 1.1 to convert the equivalent doses to account for RBE in the TPS. Dose differences ($\delta$) were calculated between the measured doses ($D_{\text{meas}}$) and the calculated doses ($D_{\text{calc}}$) using Equation (1).

$$\delta = 100 \times \frac{D_{\text{meas}} - D_{\text{calc}}}{D_{\text{calc}}} \quad \text{(1)}$$

Lateral dose profiles were measured using a 2D ionization chamber array (2D-Array, OCTAVIUS 729 XDR; PTW) and the Tough Water. The 27 x 27 array chambers are spaced 10 mm apart from center to center of each chamber. Each chamber size is 5 x 5 x 3 mm$^3$ and the chamber volume is 0.075 cm$^3$. Four lateral dose profiles of each SOBP were measured at the plateau (25 mm), proximal, middle, and distal planes. The proximal and distal planes were measured 5.0 mm inside from the 95% SOBP edge in the isocenter direction. The total measured LPs consisted of 69 planes for the 18 plans. Measured profiles were analyzed using the gamma index at the criteria of 2%/2 mm and 3%/3 mm with a dose threshold of 10% with respect to the maximum dose.

For patient-specific TPS validation, we measured the LPs at the three depths (proximal, middle, and distal) and the ADs at the isocenter for the 14 collimated beams. This measuring device was the same as that used for the dose verification of the cubic plan. Measured profiles were analyzed using the gamma index at the criteria of 2%/2 mm and 3%/3 mm, and the ADs were compared between the measured and calculated values.

3 | RESULTS

3.1 | Collimated beam measurements

Figure 4 shows two representative collimated beam results for the measured (plots) and calculated (solid lines) doses. Figure 4a,b shows the DDs both without RS (beam ranges of 135 mm and field width of 40 mm) and with RS (beam ranges of 90 mm and field width of 40 mm). Figure 4c and d show the lateral penumbra measurements (x planes) at the isocenter in the cross-section of Figure 4a,b. The average ± standard deviation (ranges) gamma index pass rates ($\gamma$-passing) at 3%/3 mm of the 12 DDs were 96.5 ± 4.0% (89.7%–100.0%). The $\gamma$-passing of 69 LPs was on average 95.2 ± 7.6% (63.0%–100.0%) at 2%/2 mm and 98.8 ± 2.9% (87.4%–100.0%) at 3%/3 mm, respectively. The AD differences at the isocenter were, on average, 0.7 ± 0.9% (−1.9%–1.8%). The lateral penumbra width differences were, on average, 0.4 ± 0.3 mm (0.1–1.1 mm) for the x-planes and 0.3 ± 0.2 mm (0.1–0.7 mm) for the y-planes. The penumbra width differences of the x-planes were within ±1.0 mm except for a plane, and that of the y-planes was ±0.7 mm.

3.2 | Patient-specific measurements

Figure 5 shows the TPS validation results for each first beam of the five clinical cases between the measurements and calculations. The $\gamma$-passing of 24 DDs were, on average, 97.7% ± 4.2% (81.7%–100.0%) at 2%/2 mm and 99.9% ± 0.4% (98.4%–100.0%) at 3%/3 mm, respectively. The AD differences at the isocenter were, on average, −0.2% ± 1.1% (−1.8%–1.8%). The AD differences were within ±1.2% for the SFO plans (the prostate and liver plans) and within ±1.8% for the MFO plan (the chordoma, C-shape, and HN plans). Although the AD difference of the MFO plan was slightly higher than that of the SFO plans, all plans were in good agreement between the measurements and calculations.

Figure 6a–d shows the histograms of the TPS validation results for AD differences, $\gamma$-passing of DDs and LPs, and lateral penumbra width differences of x and y profiles for cubic plans and clinical plan beams. Figure 7 also shows the scatter plots of LP $\gamma$-passing versus measured depth at (a) 2%/2 mm and (d) 3%/3 mm for the cubic and clinical plans. In several cubic plan’s LP measurements without RS, the $\gamma$-passing at 3%/3 mm were deteriorated (increased the measured doses). Three underestimated calculated doses in the plateau region were observed, and the $\gamma$-passing was less than 90%. Besides, the $\gamma$-passing were deteriorated below 90% at 2%/2 mm for 12 measured planes less than 75 mm depths both with and without RS plans (Table 1). To investigate the cause of the worsened $\gamma$-passing at such shallow depths, we measured the LPs and analyzed for all cubic and clinical plans by excluding the MLC. Furthermore, to verify the usefulness of MC calculations for collimated PBS plans, the gamma analyses were performed between the measured LPs and the PBS plans that were calculated using the PB algorithm. The $\gamma$-passing of uncollimated MC plans were on average 96.9% ± 3.4% (84.3%–100.0%) at 2%/2 mm and 99.6 ± 1.1% (95.6%–100.0%) at 3%/3 mm for the cubic plans and 98.3 ± 2.5% (89.3%–100.0%) at 2%/2 mm and all 100% at 3%/3 mm for the clinical plans (Figure 7b,e). Then, the $\gamma$-passing of collimated PB plans were on average 68.4 ± 23.9% (12.0%–99.4%) at 2%/2 mm and 78.7 ± 22.5% (20.0%–100.0%) at 3%/3 mm for the cubic plans and 78.4 ± 26.0% (11.1%–100.0%) at 2%/2 mm and 89.6 ± 18.6% (33.3%–100.0%) at 3%/3 mm for the clinical plans, respectively (Figure 7c,f). Although the number of measured planes with worse $\gamma$-passing (<90% at 2%/2 mm) at depths below 75 mm was reduced for the uncollimated plans than those for the collimated plans,
only three planes were showed with less than 90% of $\gamma$-passing. The collimated plans with PB showed the degraded $\gamma$-passing than these of MC at a wide depth range, confirming its unsuitability for clinical use.

4 | DISCUSSION

We performed clinical beam commissioning of the PBS plans with the MLC and evaluated whether the penumbra regions in the collimated beams were consistent between the measurements and calculations. We also verified the end-to-end test and patient-specific measurements for five collimated clinical plans.

The $\gamma$-passing at 2%/2 mm of the LPs for both cubic plans and clinical plans were on average more than 95.0%. Most measurements were satisfied the 95.0% $\gamma$-passing at 2%/2 mm for cubic plans and 3%/3 mm for clinical plans recommended by the AAPM TG-185. However, the $\gamma$-passing deteriorated (less than 90% at 2%/2 mm and 3%/3 mm) in the region of some plans less than 75 mm. We understand that the cause of the discrepancy between the measurements and calculations could be either the measurement error or the TPS dose calculation error. If this is due to measurement errors in the 2D-Array, it should be possible to see a deterioration in the $\gamma$-passing at other depths as well. Thus, we suspected the TPS modeling error rather than the measurement error. According to the TPS reference manual, the calculations on our PBS machine can be overestimated by nuclear halo if an RS is inserted, and by edge scattering if a collimator is inserted, which may change the dose calculation. Unfortunately, no previous reports on PBS systems with different collimation types have been indicated that the TPS showing modeling errors in these areas. Some of the protons near the edge of the aperture are incident on the aperture, then scatter out of the aperture again. This effect called the edge scattering effect, adds a characteristic angle to the near surface transverse dose profile, may also add dose to more central or deeper parts of the target. Since several points showed the worsen $\gamma$-passing even in uncollimated plans, the factors affecting the dose calculation error might be due to the potential limitations of evaluation of beam scattering from the MLC and the beam modeling of the TPS. The point AD differences were within ±1.9% for the 18 cubic plans and ±1.8% for the five clinical plans. These dose agreements satisfied the tolerance of within ±2.0% in the study commissioned by the same TPS of other PBS machines. In addition, several reports evaluated other PBS machines that calculated the same TPS and showed that the ADs were both within ±3.0% for cubic plans of various sizes and mock clinical cases. Since our point AD results showed a similar tendency to those reports, we judged that it was acceptable for clinical use when considered in...
conjunction with the other commissioning results. However, it should be noted that the use of collimators in shallow depth plans because in some beams with a depth of less than 75 mm the \( \gamma \)-passing of LPs may be less than 90%. If some beams have significant dose discrepancies from patient-specific measurements, they can be appropriately avoided by interventions such as revising the treatment beam angle or using uncollimated beams. Our lateral penumbra width differences were within \( \pm 1.1 \) mm. Bäumer et al. and Yasui et al. reported that the lateral penumbra width differences were within \( \pm 0.5 \) mm and \( \pm 1.5 \) mm with spot scanning systems using a patient-specific aperture,\(^{11,31}\) respectively. Vilches-Freixas et al. reported that the lateral penumbra agreements for both the left and right sides were within \( \pm 1.5 \) mm with the adaptive aperture PBS system.\(^{29}\) Our results were more consistent with those of the penumbra than their reports, except for Bäumer’s results, achieving accurate dose calculations and beam measurements. However, as Vilches-Freixas also reported, the collimator attached to a treatment nozzle such as the MLC may cause leaf position errors when moving.\(^{32}\) To treat the PBS with the MLC accurately and safely, we need to perform periodic detailed machine quality assurance of collimator position accuracy. We will evaluate additional detailed verification of the combined robustness of the beam spot position variation and collimator position variation.\(^{35}\)
Our study has explored the prospects and several limitations of TPS validations. First, only one collimator opening pattern dose distribution was verified for each target volume. As the spatial distance between the MLC and CTV reduces, the spot region and MLC overlap are expected to increase to generate a large number of collimated secondary protons, which may affect the dose calculations. In treatment planning situations, the collimator opening is freely determined for each treatment site. Therefore, we need to investigate the agreements between the calculations and measurements of the plans in which the spatial distance between the target and the MLC is different from the set value in the current study. Second, the dose verification has been performed at one type of nozzle position only. A shorter beam distance between the MLC and the patient (closer...
air gap) might lead to the dose change in the shallow region with scattered protons from the MLC. In addition, the beam with a larger air gap with RS was overestimated by the effect of the nuclear halo. This effect may cause a dose discrepancy between the measurements and the calculations. Although inserting the MLC into such a beam may increase the difficulty of dose calculation reproducibility, further consideration should be given to the calculation accuracy.

Our new PBS machine expected that collimated plans could improve lateral penumbra more than uncollimated plans. However, we still do not understand the characteristics of the PBS plans with the MLC in detail. In the future, we also plan to investigate several scenarios as shown below: (1) the robustness relationship between the collimated and uncollimated plans, (2) the changes in penumbra size for varying beam parameters, and (3) the development of a dynamic collimation PBS delivery technique.

First, in the uncollimated plans, the worst-case optimization intentionally creates a gentle dose gradient in the penumbra region. Thus, high-energy plans with a smaller beam size reduce the physical advantage of providing a sharper penumbra. In contrast, the collimated plans change the gentle dose gradient to a sharp gradient again, and unacceptable target coverage degradation may be observed if lateral setup errors occur. We will investigate the relationship between the collimator margins and target robustness. Next, several factors of changing penumbra are considered, such as spot placements, air gaps, beam sizes (depth), MLC margins, and the presence or absence of RS. In this study, we verified the dose agreements between the calculations and measurements using only one type of beam parameter. Maes et al. proposed the formulation of the penumbra width for various beam parameters in a PBS plan with a patient-specific collimator and predicted the dose advantage of the collimated plans. Our systems could also improve the quality of treatment by conducting such studies. Furthermore, the advantage of the collimated beam with MLC is that it can be irradiated while changing the position of each energy layer. To validate in advance due to the future software/hardware updates, the TPS can calculate the dynamic collimation fields by the in-house program. Smith et al. compared three types of PBS plans for five brain tumors using dynamic collimation, static collimated, and uncollimated plans. They concluded that the dynamic collimation plans could reduce the OAR doses more than the static collimated plans. We expect that the clinical use of our dynamic collimation system will provide even better proton therapy.

5 CONCLUSION

We have verified the PBS plans with the MLC calculated by the commercial MC dose engine. The commissioning results were consistent between the measurements and TPS calculations in terms of the DDs, LP, and ADs. However, the γ-passing deteriorated in several LP measurements in less than 75 mm regions. The dose calculation errors were due to the potential limitations of beam scattering from the MLC and the beam modeling of the TPS. The discrepancies in dose verifications in shallow regions can be mitigated by interventions such as using uncollimated beams or changing treatment angles. Further validations are also required because the results of this study do not cover all the commissioning of TPS in the available PBS beam conditions. To understand the characteristics of the PBS plans with the MLC in detail, we will investigate and develop the MLC dynamic collimation plans.

AUTHOR CONTRIBUTIONS

Yuki Tominaga, Yusuke Sakurai, Junya Miyata, and Masataka Oita conceived and designed the study, collected the data, contributed data or analysis tools, performed the analysis, wrote the paper, and revised the paper. Shuichi Harada and Takashi Akagi provided clinical expertise and supervision of the project.

ACKNOWLEDGMENTS

The authors would like to thank the staff of the Medical Co. Hakuhokai, Osaka Proton Therapy Clinic, for their cooperation in obtaining experimental data for this study.

CONFLICT OF INTEREST

The authors declare that they have no conflicts of interest.

ORCID

Yuki Tominaga https://orcid.org/0000-0002-7851-6213
Masataka Oita https://orcid.org/0000-0002-8667-6209

REFERENCES

1. Van De Water TA, Lomax AJ, Bijl HP, et al. Potential benefits of scanned intensity-modulated proton therapy versus advanced photon therapy with regard to sparing of the salivary glands in oropharyngeal cancer. Int J Radiat Oncol Biol Phys. 2011;79(4):1216-1224.
2. Pedroni E, Bacher R, Blattmann H, et al. The 200-MeV proton therapy project at the Paul Scherrer Institute: conceptual design and practical realization. Med Phys. 1995;22(1):37-53.
3. Zhu XR, Poenisch F, Li M, et al. Commissioning dose computation models for spot scanning proton beams in water for a commercially available treatment planning system. Med Phys. 2013;40(4):041723.
4. Zhang X, Li Y, Pan X, et al. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage iiiib non-small-cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys. 2010;77(2):357-366.
1. Tominaga Y, Sakurai Y, Miyata J, Harada S, Akagi T, Oita M. Validation of pencil beam scanning proton therapy with multi-leaf collimator calculated by a commercial Monte Carlo dose engine. J Appl Clin Med Phys. 2022;23:e13817. https://doi.org/10.1002/acm2.13817

2. Ezzell GA, Burmeister JW, Dogan N, et al. IMRT commissioning: multiple institution planning and dosimetry comparisons, a report from AAPM Task Group 119. Med Phys. 2009;36(11):5359-5373.

3. Fredriksson A, Forsgren A, Härdermark B. Minimax optimization for handling range and setup uncertainties in proton therapy. Med Phys. 2011;38(3):1672-1684.

4. Liu W, Zhang X, Li Y, Mohan R. Robust optimization of intensity modulated proton therapy. Med Phys. 2012;39(2):1079-1091.

5. Shirey RJ, Wu HT. Quantifying the effect of air gap, depth, and range shifter thickness on TPS dosimetric accuracy in superficial PBS proton therapy. J Appl Clin Med Phys. 2018;19(1):164-173.

6. Carabe A, Moteabbed M, Depauw N, Schuemann J, Paganetti H. Parametric characterization of a short-range applicator for treating superficial moving tumors with respiratory-gated spot-scanning proton therapy using real-time image guidance. Phys Med Biol. 2016;61(4):1515-1531.

7. Schreuder AN, Bridges DS, Rinaldi I, et al. A pencil beam algorithm for intensity-modulated proton therapy systems: report of AAPM task group 185. Med Phys. 2021;48(1):e1-e30.

8. Saini J, Maes D, Egan A, et al. Dosimetric evaluation of a short-range applicator for treating superficial moving tumors with respiratory-gated spot-scanning proton therapy using real-time image guidance. Phys Med Biol. 2016;61(4):1515-1531.

9. Meier G, Leiser D, Besson R, et al. Contour scanning for penumbra improvement in pencil beam scanned proton therapy. Phys Med Biol. 2017;62(6):2398-2416.

10. Krailik JC, Xi L, Solberg TD, Simone CB, Lin L. Comparing proton treatment plans of pediatric brain tumors in two pencil beam scanning nozzles with different spot sizes. J Appl Clin Med Phys. 2015;16(6):41-50.

11. Miyata J, Harada S, Akagi T, Oita M. Validation of a short-range applicator for treating superficial moving tumors with respiratory-gated spot-scanning proton therapy using real-time image guidance. Phys Med Biol. 2016;61(4):1515-1531.

12. Winterhalter C, Meier G, Oxley D, Weber DC, Lomax AJ, Safai T. Beam commissioning of intensity-modulated proton therapy systems: report of AAPM task group 119. Med Phys. 2009;36(11):5359-5373.

13. Farr JB, Moyers MF, Allgower CE, et al. Clinical commissioning of intensity-modulated proton therapy systems: report of AAPM task group 185. Med Phys. 2021;48(1):e1-e30.

14. Low DA, Harms WB, Mutic S, Purdy JA. A technique for the quantitative evaluation of dose distributions. Med Phys. 1998;25(5):656-661.

15. Schreuder AN, Bridges DS, Rinaldi I, et al. Beam commissioning of the first compact proton therapy system with spot scanning and dynamic field collimation. Br J Radiol. 2020;93(1107):20190598.

16. Smith B, Gelover E, Moignier A, et al. Technical note: a treatment log file for handling range and setup uncertainties in proton therapy. Phys Med Biol. 2011;38(3):1672-1684.

17. Smith B, Gelover E, Moignier A, et al. Technical note: a treatment log file for handling range and setup uncertainties in proton therapy. Phys Med Biol. 2011;38(3):1672-1684.

18. Smith B, Gelover E, Moignier A, et al. Technical note: a treatment log file for handling range and setup uncertainties in proton therapy. Phys Med Biol. 2011;38(3):1672-1684.

19. Smith B, Gelover E, Moignier A, et al. Technical note: a treatment log file for handling range and setup uncertainties in proton therapy. Phys Med Biol. 2011;38(3):1672-1684.

20. Smith B, Gelover E, Moignier A, et al. Technical note: a treatment log file for handling range and setup uncertainties in proton therapy. Phys Med Biol. 2011;38(3):1672-1684.

21. Smith B, Gelover E, Moignier A, et al. Technical note: a treatment log file for handling range and setup uncertainties in proton therapy. Phys Med Biol. 2011;38(3):1672-1684.